To examine the possible receptor-ligand pairs mediating adhesion of activated and "unactivated" platelets to leukocytes and the kinetics of leukocyte-platelet binding, we developed a flow cytometric assay using isolated cell fractions to accurately measure heterotypic cell adhesion, including both total leukocyte-platelet conjugate formation as well as the number of platelets bound per leukocyte. We have shown that (1) activated platelet binding to both polymorphonuclear leukocytes (PMN) and monocytes is dependent on both a specific epitope (blocked by monoclonal antibody G I ) of granule membrane protein-I40 (GMP-140) and the pres-CTIVATED PLATELET adhesion to polymorphonu-A clear leukocytes (PMN) and monocytes has been shown to be mediated by the selectin molecule, platelet activation-dependent granule external membrane/granule membrane protein-140 (PADGEM/GMP-140).'-' The microscopic assays for such heterotypic cell adhe~ion,~ ie, counting of adherent cell events, are cumbersome and may not be sensitive enough to discern more subtle binding of unactivated platelets or differences in binding that may reflect different adhesion receptor functions or affinities. We have developed a flow cytometric assay that accurately quantitates platelet-leukocyte adhesion with regard to the percentage of leukocytes binding platelets and the relative number of platelets bound per leukocyte. Using this assay, we have determined that significant percentages of neutrophils and monocytes bind unactivated platelets in quantitatively different fashions and with different kinetics. Unactivated platelet binding to PMN and, in part, to monocytes is not mediated through divalent cations or the G1 blocking epitope of PADGEM/GMP-140 (also designated CD62), unlike activated platelet binding. These results further clarify the specific platelet and leukocyte receptors responsible for heterotypic cell adhesion.
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negative controls. The MoAbs 1E3' and G1' (the latter kindly donated by Dr R. McEver, University of Oklahoma, Oklahoma City) are both specific for GMP-l40/PADGEM, but only G1 inhibits adhesion of stimulated platelets to neutrophils. SZ26 (AMAC, Inc, Westbrook, ME) recognizes glycoprotein Ib (GPIb), P2' (AMAC) is specific for GPIIb/IIIa, and both 80H58 (AMAC) and MMA9 (Leu-M1; Becton Dickinson Immunocytometry Systems, San Jose, CA) recognize CD15. D12I0 (Leu-15; Becton Dickinson) recognizes the LeuCAM CDllb ("MAC-1"). MoAb 7E3" (gift of Dr B. Coller, SUNY, Stony Brook, NY) blocks fibrinogen binding to GPIIb/IIIa, RIBS-l'* binds to a neo-epitope on fibrinogen appearing after GPIIb/IIIa adhesion, LIBS-1" recognizes a new GPIIb/IIIa epitope exposed by fibrinogen binding, and TSP1-1I4 recognizes thrombospondin (the latter three MoAbs were the gift of Dr E. Plow, Scripps Clinic, La Jolla, CA). MoAbs Mo2" (anti-CD14) and Mo3eI6 recognize quiescent and activated monocytes, respectively (gift of Dr R. Todd, University of Michigan, Ann Arbor, MI); OKM5" binds to GPIV (gift of Dr P. Rao, R.W. Johnson Pharmaceutical Research Institute, Raritan, NJ). MoAb RR 1/1, an anti-intercellular adhesion molecule-1 (anti-ICAM-1)18 and R3.3, ax1ti-CD18,'~ were the kind gift of Dr R. Rothlein (Boehringer-Ingelheim, Ridgefield, CT). 80H5, MMA, Mo2, and Mo3e are murine IgM MoAbs; all other MoAbs are murine IgG,, except for anti-CDllb, which is a murine IgG,,.
The human tumor cell line U93720 was supplied by S. Mella (Yale Comprehensive Cancer Center, New Haven, CT). The cells were maintained with RPMI 1640 containing 10% fetal calf serum (FCS) supplemented with penicillin/streptomycin and L-glutamine. Cells were passaged three times weekly. For coincubation studies, U937 cells were washed three times and resuspended in Tyrode's-HEPES buffe?' (HEPES 5 mmol/L, NaCl 140 mmol/L, KCI 2.7 mmol/L, dextrose 5.5 mmol/L, NaH,PO, 0.42 mmol/L, and NaHCO, 12 mmol/L, pH 7.4) with 2 mg/mL bovine serum albumin (TH-BSA) at a count of 3 x 106/mL. Trypan blue exclusion showed greater than 98% viability.
Platelet-rich plasma (PRP) was prepared from citrated normal human blood; PRP was then gel-filteredu using Sepharose 2B (Pharmacia, Piscataway, NJ) in TH-BSA and counts adjusted to 10*/mL. Seven milliliters of the platelet suspension was stimulated with bovine thrombin (Sigma, St Louis, MO) at a final concentration of 0.1 to 0.25 U/mL or adenosine diphosphate (ADP; Sigma) at a final concentration of 5 Kmol/L or diluent at 37°C for 10 minutes. One milliliter of 8% paraformaldehyde was then added and the sample kept at room temperature for 60 minutes. One milliliter of Tris-glycine solution (250 mmol/L Tris and 500 mmol/L glycine) was added to stop fixation.' After 15 minutes at 22T, the samples were washed three times in TH buffer and resuspended at a concentration of 3 x 108/mL. Manual counts showed less than 1% contamination with leukocytes and erythrocytes and less than 5% loss of platelets due to thrombin-induced For personal use only. on August 16, 2017 . by guest www.bloodjournal.org From clumping, By gently resuspending platelets after thrombin stimulation,'~' the percentage of small aggregates produced was less than 3% of the total number of platelets, compared with 1% of unactivated platelets as measured by manual counts using EDTAU and flow cytometry." PMN isolation. Isolation of PMN from heparinized whole blood from the platelet donor was performed as previously reported' using Mono-poly resolving media (Flow Labs, Maclean, VA). PMN were then washed and resuspended in TH buffer at a final count of 3 x 106/mL. No platelets could be detected in this preparation of PMN by manual counting. PMN were greater than 95% pure and 99% viable by trypan-blue exclusion.
Purification of platelet-depleted PBMC from the platelet donor was accomplished using the method of Pawlowski et Briefly, PRP was removed from whole blood anticoagulated with 5 mmol/L EDTA.
An equal volume of TH with 5 mmol/L EDTA (TH-EDTA) was mixed with the remaining blood. PBMC were then isolated using standard differential centrifugation with Ficoll-Hypaque (Pharmacia). PBMC were then washed twice in TH-EDTA and centrifuged at 12% for 15 minutes. The supernatant was discarded and the cells resuspended in cold phosphate-buffered saline (PBS). Cells were centrifuged again at 120g for 15 minutes and then resuspended in 2 mL of autologous serum with 5 mmol/L EDTA for 15 minutes at 3TC, vortexed, and centrifuged again at 12% for 15 minutes. The serum incubation and centrifugation were repeated once, and the cells were resuspended in TH buffer at a count of 3 x 106/mL. Manual counts showed a greater than 2-log reduction of the plate1et:PBMC ratio with a final plate1et:PBMC ratio of 1:l. Between 40% and 50% of the PBMC were monocytes; trypan blue exclusion showed greater than 95% viability.
Platelets (150 pL) were incubated with saturating concentrations of fluorescein isothiocyanate (FITC)-conjugated or biotinylated anti-GPIb (SZ2; AMAC) or anti-GPIIb/ IIIa (P2; M A C ) MoAbs for 20 minutes, then washed and resuspended in 150 pL TH buffer with 2 mmol/L CaCI, (TH-Ca). The biotinylated samples were then incubated with saturating concentrations of phycoerythrin (PE)-avidin (Becton Dickinson) for 20 minutes, washed, and resuspended in 150 pL of TH-Ca.Z6 Most studies were performed using GPIIb/IIIa as the platelet marker. U937 and PMN were similarly labeled with FITC-anti-CD45 (HLE; Becton Dickinson) and PBMC were labeled with PE-antLCD14 (Leu-M3; Becton Dickinson) MoAbs and resuspended in 150 pL TH-Ca. This CD45 isoform is present on PMN, monocytes, and lymphocytes but neither erythroid cells nor platel e t~.~' CD14 is specific for monocytes and is not present on lymphocytes."
For determination of the percentage of platelets expressing GMP-140, platelets were incubated with saturating concentrations of FITC-anti-GPIIb/IIIa and biotinylated anti-GMP-140 (MoAb 1E3), washed and incubated with PE-avidin (as above), and then analyzed on the FACScan as previously rep~rted.'~ One hundred and fifty microliters of the fixed-labeled platelets was added to 150 pL of viable-labeled PMN or PBMC (yielding a final concentration of 1.5 x lo8 platelets/mL and 1.5 x lo6 leukocytedml to approximate the relative concentrations in normal blood) in a 12 x 75 mm polystyrene tube, capped, and mixed using an end-over-end rockerz9 at 22°C. All coincubation experiments were performed in TH buffer with 2 mmol/L CaC1,. For time-course experiments, the tube was placed on the FACScan at specific intervals, studied for less than 10 seconds, recapped, and returned to the rocker. The time-course experiments showed that heterotypic cell adhesion was maximal after 30 minutes of coincubation. Therefore, all static experiments were studied after 30
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Coincubation assay. minutes of coincubation. Preliminary experiments also showed that fluorescent labeling of leukocytes and platelets after the coincubation assay yielded equivalent results to prelabeling of cells. The latter technique was found to be more efficient for timed sampling.
For blocking studies, Arg-Gly-Asp-Ser (RGDS)" peptide (Peninsula Laboratories, Inc, Belmont, CA) at a final concentration of 1 mg/mL or MoAbs were added to the desired cell fraction for 20 minutes at 22°C before coincubation. The final concentration of each MoAb was 10 pg/mL, except for the G1 Fab,, which was 1 pg/mL. Although fixation may diminish binding of some MoAbs to platelets, saturating concentrations of these MoAbs were determined by flow analysis and corresponded well to their reported blocking concentration^.'^'^^^^'^ For divalent cation depletion studies, EDTA (Sigma) was added to each cell fraction at a final concentration of 1 mmol/L for 20 minutes before coincubation. Experiments were also performed using cells resuspended in TH-Ca with 2 mg/mL BSA no difference was seen compared with TH-Ca. For bead experiments, fluorescent platelet-sized (inert) beads (Becton Dickinson) at a concentration of 3 x 108/mL in TH-Ca were substituted for platelets and coincubated in an identical manner.
Flow cytometry. Samples were analyzed on a FACScan flow cytometer (Becton Dickinson) with data stored in list mode files. The determination of the percentage of platelets expressing GMP-140 was performed as previously described," using a threshold set with a PE-conjugated, isotype-matched control MoAb. Live gating on leukocyte-sized events was then performed to exclude single platelets using either forward and side scatter alone or in combination with a specific leukocyte fluorescent marker. Ten thousand events were measured for each sample. An isotypematched control antibody was used to set a threshold (99% of events below the threshold) for positive platelet marker fluorescence. The percentage of leukocytes binding platelets was then expressed as the percentage of leukocytes with positive platelet marker fluorescence, ie, above the threshold (Fig 1) . Both the percentage of leukocytes with positive platelet fluorescence and the mean platelet marker fluorescence of the positive leukocytes were measured. Except for the data in Table 1 , all experiments were performed at least three times, with a single representative experiment shown in the figures.
The mean platelet marker fluorescence (total platelet fluorescence) of the positive leukocytes was then converted to a relative index of the number of platelets bound per leukocyte (platelet fluorescence ratio) in the following manner. For each experiment, a sample of unactivated fixed platelets labeled identically (with MoAb SZ2 or P2) to platelets in the coincubation assay was analyzed in the platelet-size range using a narrow forward scatter (size) gate. The mean fluorescence of the platelets in this gate corresponds to a standard fluorescence for single plateletsz4; this number was slightly higher for GPIIb/IIIa and slightly lower for GPIb expression on activated platelets, as e x p e~t e d . '~.~ Total platelet fluorescence of the heterotypic cell conjugates was then divided by this standard single platelet fluorescence to yield the final platelet fluorescence ratio, rounded to the nearest whole number. Because the fluorescence of GPIIb/IIIa per platelet does increase with activation, the fluorescence ratio must be interpreted as only a relative number. This ratio was never less than 1 for any leukocyte-platelet conjugate and, when compared with microscopic examination of the conjugates, yielded a semiquantitative estimate of the number of platelets bound per leukocyte. It is also important to note that changes in the fluorescence intensity of the platelet markers did not affect the determination of the percentages of leukocyte-platelet conjugates. 
RESULTS
Cell fractions of purified platelets, PMN, PBMC, or U937 were isolated as described. Figure 1 shows the dot plots of a Flow cytometric assay of heterotypic cell adhesion.
representative assay in which PMN were labeled with FITC-anti-CD45 and platelets with PE-anti-GPIIb/IIIa or PE-control MoAb. Only leukocyte-sized events that were FITC-positive were acquired. Two CD45' populations were identified: CD45 bright and CD45 dim. As previously de~cribed;~ the CD45 bright population includes the few contaminating lymphocytes. Analysis of PMN binding was therefore limited to the CD45 dim PMN population (analysis gate in Fig 1A) . A threshold marker for platelet fluorescence was set using the PE-control ( Fig 1A and B) ; events that were above this threshold marker therefore represent PMN with bound platelets.
When unactivated platelets were incubated with PMN for 30 minutes and analyzed, 30% of PMN bound platelets (Fig 1C and D) . When PMN were similarly incubated with thrombin-activated platelets, 85% of PMN bound platelets (Fig 1E and F) . In addition to measuring the percentage of PMN with bound platelets, the total platelet fluorescence per PMN was also determined and corrected using the standard to give the platelet fluorescence ratio, a semiquantitative estimate of the number of platelets bound per PMN, as described in Materials and Methods. As seen in Fig lD, this platelet fluorescence ratio was 2 for unactivated platelets bound to PMN, while activated platelet binding to PMN (Fig 1F) had a ratio of 22. (Note that the fluorescence is on a log scale.) Substituting GPIb as a platelet marker for GPIIb/IIIa yielded similar results for PMN adhesion to activated and unactivated platelets. In PBMC-platelet assays, monocytes were similarly analyzed using the PE-anti-CD14 labeling to exclude lymphocytes and FITC-anti-GPIIb/IIIa fluorescence to quantitate platelet adhesion.
To eliminate the possibility that events with both FITC and PE fluorescence represent the passage of unbound platelets and PMN simultaneously through the detection chamber, experiments were performed in which fluorescent platelet-sized inert beads were substituted for the platelets and coincubated with both U937 and PMN. No dualfluorescent events above the threshold were detected under these conditions. This finding confirms that the assay does not measure simultaneous passage of platelets with PMN or U937 cells through the cytometer laser but rather platelets bound to leukocytes.
In six preliminary experiments, manual counting of the percentage of leukocytes with at least one bound platelet was on average 5% less than the percentage derived from fluorescence values. The platelet fluorescence ratios for leukocytes binding unactivated platelets averaged 2 to 4, corresponding to manual counts averaging one to two platelets bound per U937 cell or PMN. When thrombin- For
platelets were bound to PMN or U937 cells, platelet fluorescence ratios increased fivefold on average and correlated with microscopic examination of either 5 to 10 platelets rosetted around each leukocyte or clumps of platelets adherent to leukocytes. Therefore, in this assay, the total platelet fluorescence and calculated platelet fluorescence ratio of the cell-cell conjugates may be used as estimates of the number of platelets bound per leukocyte, while the percentage of platelet-marker-positive conjugates represents the percentage of leukocytes binding at least one platelet.
Flow cytometnc assay of GMP-I40 eqression on platelets. As shown in Fig 2, on average, 7% of "unactivated" platelets expressed low levels of GMP-140 (mean GMP-140 fluorescence 14 in arbitrary units), as recognized by MoAb 1E3. At thrombin doses of 0.1 to 0.25 U/mL, 100% of activated platelets expressed high levels (mean fluorescence, 165) of GMP-140?, while 5 pmol/L ADP-stimulated gel-filtered platelets had much lower GMP-140 expression (mean fluorescence, 25) on 30% of platelets. Experiments in which prostaglandin E, (PGE,) 10 nmol/L' was included in the platelet preparation had no effect on GMP-140 expression for unactivated or activated platelets; leukocyteplatelet adhesion was similarly unaffected. These data indicate that a small percentage of "unactivated" platelets express low levels of GMP-140 on their surface while the majority of platelets have no detectable GMP-140. Although we did not make a direct comparison, it is possible that the flow cytometry assay for surface GMP-140 is less sensitive than other direct methods; however, the minimal expression of GMP-140 by flow immunofluorescence on unstimulated, washed platelets is comparable with data from Stenberg et a1 using immunocytochemical technique~.'~ When viable U937 cells were incubated with fixed platelets for 30 minutes, on average, 17% of U937 cells bound unactivated platelets with a mean platelet fluorescence ratio of 2 (Table 1) . When thrombin-activated platelets were incubated with U937 cells, 61% of U937 cells bound platelets, and the conjugates demonstrated a fluorescence ratio of 8 ( Table   Heterotypic cell ~~i !? ! 100 1). The percentage of U937 cells that bound ADP-activated platelets averaged 30% with a mean fluorescence ratio of 3. When unactivated platelets were combined with autologous PMN, 34% of PMN bound platelets with a mean fluorescence ratio of 4. Thrombin activation of platelets resulted in 82% of PMN binding platelets with a mean ratio of 19, a fivefold increase. When ADP-stimulated platelets were used, only 40% of PMN bound platelets, with a minimal increase in the number of platelets bound per PMN (Table 1) .
Unlike PMN, a much higher percentage (87%) of monocytes bound unactivated platelets at baseline; this percentage was 93% for thrombin-activated platelets (Table 1) . However, like PMN, the fluorescence ratio, ie, the relative number of platelets per leukocyte, for activated platelet binding was six times higher than the ratio for unactivated platelet binding (5 v 30) .
For PMN, incubation with activated platelets resulted in the maximum percentage of binding within 2 minutes and varied little over the next 60 minutes (Fig 3A) . Binding to unactivated platelets followed a similar pattern. The relative number of unactivated platelets bound per PMN (Fig 3B) did not significantly change over 60 minutes. However, the number of activated platelets bound per PMN gradually increased over 30 minutes, reaching a plateau at that time-point.
The kinetics of monocyte binding to platelets was distinct from that of PMN. For binding to unactivated and activated platelets, the percentage of monocyte-platelet conjugate formation was not maximal immediately (Fig 4A) . At 2 minutes after incubation, binding was only 70% of the peak and gradually increased, reaching a plateau at 30 minutes and remaining unchanged for the next 30 minutes. The relative numbers of unactivated platelets bound per monocyte (Fig 4B) ments). However, unactivated platelet adhesion to PMN was unaffected by the blocking MoAb to GMP-140 or by EDTA. In addition, this inhibition by G1 or EDTA reduced the percentage of PMN binding activated platelets to less than the percentage binding unactivated platelets. The fluorescence ratio was also significantly reduced by the MoAb G1, Fab, fragments of G1, and EDTA (Fig 5) , but not as low as the unactivated platelet ratios. The control MoAb 1E3 (which recognizes a nonadhesion epitope of GMP-140) had no effect on PMN binding of either activated or unactivated platelets. Other MoAbs that did not inhibit either unactivated or activated platelet binding to PMN included SZ2, RIBS-1, LIBS-1, TSP1-1, 7E3, and OKM5; RGDS peptide also had no effect.
Like PMN, the percentage of monocytes binding activated platelets was blocked to levels significantly lower than for unactivated platelet binding by G1 Fab, and EDTA (Fig  7) . 1E3 again had no effect. RGDS peptide and the blocking MoAbs OKM5, RIBS-1, LIBS-1, TSP1-1, and 7E3 had no effect on activated platelet binding to monocytes.
There was partial blocking of unactivated platelet binding by G1 Fab, and EDTA, although much less than with activated platelets. The mean fluorescence ratio for the number of platelets bound per monocyte was also reduced by G1, 7E3, and EDTA, but was still higher than for unactivated platelets per monocyte. 7E3 (recognizing GPIIb/IIIa)" was the only MoAb other than G1 that blocked unactivated platelet binding to monocytes and did so to a similar extent as EDTA or G1 Fab,. Using different concentrations of 7E3 to establish a "dose-response curve" for blocking unactivated platelet binding showed that partial blocking reached a plateau at the 10 kg/mL concentration. Incubation of unactivated platelets with G1 Fab, and 7E3 simultaneously showed no additive inhibition compared with either MoAb alone.
Putative PMN and monocyte receptors for binding platelets. PMN were preincubated with a panel of MoAbs before coincubation with activated platelets (Fig 8) . Only 80H5, directed against CD15, partially inhibited PMN adhesion to activated platelets. However, 8OH5 inhibition was minimal when compared with inhibition of activated platelet binding by G1. MMA, another anti-CD15 MoAb, had no inhibitory For personal use only. on August 16, 2017 . by guest www.bloodjournal.org From effect on adhesion, suggesting that either the effect of SOH5 was nonspecific and a consequence of steric hindrance by this IgM MoAb or, less likely, that SOH5 and MMA recognize slightly different epitopes of the CD15 carbohydrate. RGDS, TSP1-1, anti-ICAM-1, anti-CD18, and anti-CD1 l b had no effect on either the percentage of binding or the number of activated platelets per PMN. Neither RGDS nor any MoAb, including 80H5, incubated with PMN before unactivated platelet binding had any effect on cell conjugate formation.
When MoAbs were preincubated with monocytes, 80H5, but not MMA, similarly demonstrated slight inhibition of binding to activated platelets when compared with the G1 MoAb. Activated platelet binding to monocytes was unaffected by RGDS, TSPl-1, Mo2, Mo3e, anti-ICAM-1, anti-CD18,OKM5, and anti-CDllb. However, 7E3, preincubated with monocytes, inhibited both the percentage of monocyte binding to unactivated platelets and the number of platelets per monocyte, but had no effect on activated platelet binding to monocytes (Fig 9) . 
DISCUSSION
Heterotypic cell-platelet adhesion on the cytometer may be measured with sufficient sensitivity by this assay to allow detailed studies of leukocyte-platelet conjugate formation and the involved receptor-ligand pairs. The measurement of 10,000 leukocytes per sample provides increased sensitivity for even low-level alterations in cell-cell adhesion. Using this assay, these studies demonstrate two observations that have not been previously appreciated: (1) the baseline binding of unactivated platelets to a significant percentage of U937 cells and leukocytes (34% of PMN and 87% of monocytes); and (2) the differences in PMN and monocyte adhesion to platelets in terms of the kinetics of binding, the percentages of cells that bind platelets, and the semiquantitative measure of the number of platelets bound per leukocyte. This study also confirms the specific receptor interactions between activated platelets and leukocytes reported by others."' In addition, we have begun to elucidate the conditions by which unactivated platelets adhere to PMN and monocytes.
Patterns of platelet binding varied between cells. When thrombin-activated platelets were added to cell fractions, 93% of monocytes, 82% of PMN, and 61% of U937 cells bound platelets. For both PMN and U937 cells, this finding represents more than a doubling of the number of cells that bound platelets compared with the number that adhered to unactivated platelets. In contrast, the majority of monocytes are capable of binding at least one unactivated platelet, and the percentage of monocytes binding platelets did not increase significantly when activated platelets were used. The platelet fluorescence ratio (roughly the number of platelets bound per cell) for binding of activated platelets was 5 to 10 times higher than for binding of unactivated platelets to U937 cells and both leukocyte fractions. Platelets stimulated with ADP, which caused GMP-140 expression in only 30% to 40% of the platelets and at quantitatively low levels per platelet compared with thrombin, showed very little increased adhesion to PMN and U937 cells.
PMN and monocytes differed also with respect to their kinetics of platelet adhesion. For both unactivated and activated platelet binding to viable PMN, the total number of PMN capable of binding at least one platelet rapidly reached equilibirum, and the number of activated platelets bound per PMN steadily increased before reaching a plateau at 30 minutes, similar to the kinetics of PMN binding solubilized GMP-140." The time-course of activated platelet-PMN binding may therefore be solely diffusion-dependent. The alternative hypothesis is that the increasing number of platelets bound per PMN over time results from platelet adhesion to PMN receptors that were not immediately accessible. The latter possibility would imply dynamic changes in the PMN after activated platelet adhesion; however, this hypothesis is unlikely because other investigators have found that activation of PMN does not increase GMP-140 adhesion"g and that fixed PMN bind soluble GMP-140 with the same kinetics as fresh PMN.
In contrast to PMN, only 70% of the monocytes bound
For personal use only. on August 16, 2017 . by guest www.bloodjournal.org From platelets (activated or unactivated) within 2 minutes, and binding to the remaining monocytes occurred gradually over 30 minutes. The number of unactivated platelets bound per monocyte remained low in contrast to the number of activated platelets bound per monocyte, which continued to increase over 60 minutes, suggesting that the kinetics of monocyte adhesion to activated platelets differs from PMN. This may be the result of a different diffusion rate for monocyte-platelet interaction compared with PMN or may be the consequence of changes in monocyte receptors after initial platelet adhesion. It is also possible that this difference is due to lymphocytes in the PBMC fraction interfering with monocyte-platelet adhesion via competition for available platelets. However, we have demonstrated that fewer than 30% of lymphocytes bind unactivated platelets and that this binding does not increase with addition of thrombin-stimulated platelets (data not shown), as noted by Moore et al." In addition, the 100-fold excess of platelets was saturating for monocyte adhesion in preliminary experiments. Thus, the possibility that initial monocyteplatelet adhesion enhances platelet-binding capabilities over 30 to 60 minutes remains viable and a subject for future investigation.
Binding of PMN or monocytes to activated platelets was clearly dependent on the epitope of PADGEM/GMP-140 recognized by MoAb G1 (but not the epitope recognized by 1E3) and on the presence of divalent cations, as noted previously.'Z2 No other MoAb inhibited activated platelets from binding leukocytes, including antibodies to GPIV and thrombospondin, in contrast to data from Silverstein et al, who also used OKM5 to block GPIV.2L,29 Because G1 or EDTA reduced the percentage of leukocytes binding activated platelets to levels below that seen with unactivated platelets, we infer that the receptor(s) on unactivated platelets that mediate adherence to PMN and monocytes are rendered nonfunctional by thrombin activation of platelets. Whether this result is due to a conformational change in the receptor, cleavage of the receptor's extracellular portion that mediates adhesion, or inhibition or downregulation of its expression will require identification of the receptor.
The inability of G1 or EDTA to inhibit unactivated platelet adhesion to PMN demonstrates that unactivated platelet binding is not dependent on divalent cations and appears to be mediated through a platelet receptor other than GMP-140 or through a separate domain on GMP-140 not blocked by G1. Monocyte adhesion to unactivated platelets was only partially inhibited by EDTA or G1 and not to the degree that activated platelets were inhibited. Because 2% to 10% of platelets in the "unactivated" sample express low amounts of GMP-140, it is possible that partial inhibition of binding by G1 or EDTA is a result of activated platelet "contamination" of the unactivated sample. However, the quantitative level of unactivated platelet binding to monocytes that remains after G1 or EDTA inhibition cannot be solely explained by activated platelet "contamination." Because PMN binding to unactivated platelets was not affected by G1, the data suggest that monocytes may have enhanced abilities to bind platelet receptors, such as low levels of GMP-140.
The 7E3 MoAb partially blocked unactivated platelet binding to monocytes. This result was in contrast to other MoAbs that recognize GPIIb/IIIa, LIBS-1 and P2, and RGDS peptide that showed no inhibition of unactivated platelet binding to monocytes. 7E3 blocks fibrinogen binding to GPIIb/IIIa and binds to activated and unactivated platelets," albeit with different kinetics. 7E3 binding to unactivated platelets is near-maximal after 30 These intriguing findings regarding unactivated platelet binding to monocytes must, however, be interpreted cautiously for several reasons. In these experiments, 7E3 was not used as an Fab, fragment and therefore, we may be measuring steric hindrance of adhesion, perhaps through monocyte Fc receptor binding of 7E3, although other MoAbs of the same murine isotype did not block adhesion in this study. As noted in Materials and Methods, purified monocytes will often have an associated single platelet; therefore, 7E3 may also block a receptor on platelets that are "contaminating" the monocyte preparation and thus preventing recruitment of new platelets to the conjugate via homotypic adhesion, albeit a non-RGDSdependent site. Finally, it must be emphasized that "unactivated" platelets are defined here as not having undergone significant a-granule release, as determined by GMP-140 expression. It is possible that despite using k e d gel-filtered platelets and incorporating PGE, into some assays, unactivated platelets may have altered conformation of some adhesive molecules compared with native, circulating platelets.
We found that blockade of CD15 on the leukocyte with MoAb 80H5, but not with MMA, slightly decreased monocyte and PMN adherence to activated platelets. This finding suggests a nonspecific effect of the IgM MoAb 80H5 and does not confirm CD15 as the leukocyte receptor for GMP-140, in contrast to data from Larsen et a1.3l Other investigators have not found that CD15 mediates adhesion of activated platelets; rather, a sialated glycoprotein, as yet unidentified, has been suggested as the constitutive receptor for GMP-140 on platelet^?^.^' The epitopes that we tested on CDllb, CD18, and ICAh4-1 on neutrophils and monocytes did not appear to be candidates for adhesive receptors, nor did RGDS have any inhibition of monocyte For personal use only. on August 16, 2017 . by guest www.bloodjournal.org From or PMN adhesion to platelets. The MoAbs Mo2, Mo3e, and OKM5 (anti-GPIV), directed against monocyte-specific receptors, and TSP1-1, directed against the GPIV-ligand, thrombospondin, also did not inhibit monocyte adhesion to platelets.
Leukocyte-platelet adhesion may be of physiologic significance because platelets have been shown to supply free cholesterol to monocytes, which may then become involved in foam cell generation of atherosclerotic lesion^.^^^^^ Platelets may also deliver prostaglandin metabolites to leukocytes, which in turn inhibit platelet function.40 Further sensitive studies of heterotypic cell adhesion and metabolic cooperation will hopefully aid in the characterization of the responsible platelet and leukocyte receptors and in the investigation of the functional consequences of adhesion for both cell types.
